Aperio Group LLC boosted its stake in Mallinckrodt PLC (NYSE:MNK) by 35.5% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 58,362 shares of the company’s stock after buying an additional 15,301 shares during the period. Aperio Group LLC owned approximately 0.06% of Mallinckrodt PLC worth $2,181,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently modified their holdings of MNK. OppenheimerFunds Inc. raised its holdings in Mallinckrodt PLC by 23.1% in the 1st quarter. OppenheimerFunds Inc. now owns 8,887 shares of the company’s stock valued at $396,000 after buying an additional 1,666 shares during the period. Wellington Management Group LLP purchased a new stake in Mallinckrodt PLC in the 1st quarter valued at about $373,000. Teachers Advisors LLC raised its holdings in Mallinckrodt PLC by 4.3% in the 1st quarter. Teachers Advisors LLC now owns 187,286 shares of the company’s stock valued at $8,347,000 after buying an additional 7,753 shares during the period. Amalgamated Bank raised its holdings in Mallinckrodt PLC by 6.2% in the 1st quarter. Amalgamated Bank now owns 7,625 shares of the company’s stock valued at $340,000 after buying an additional 447 shares during the period. Finally, Xact Kapitalforvaltning AB raised its holdings in Mallinckrodt PLC by 4.6% in the 2nd quarter. Xact Kapitalforvaltning AB now owns 8,525 shares of the company’s stock valued at $382,000 after buying an additional 374 shares during the period. Hedge funds and other institutional investors own 98.83% of the company’s stock.
Several analysts recently issued reports on the stock. UBS AG lowered shares of Mallinckrodt PLC from a “buy” rating to a “neutral” rating and set a $24.00 price objective on the stock. in a report on Monday. Canaccord Genuity reduced their price objective on shares of Mallinckrodt PLC from $38.00 to $24.00 and set a “buy” rating on the stock in a report on Wednesday, November 8th. Stifel Nicolaus reduced their price objective on shares of Mallinckrodt PLC from $70.00 to $50.00 and set a “buy” rating on the stock in a report on Wednesday, November 8th. Morgan Stanley reduced their price objective on shares of Mallinckrodt PLC from $40.00 to $27.00 and set an “equal weight” rating on the stock in a report on Wednesday, November 8th. Finally, BMO Capital Markets reduced their price objective on shares of Mallinckrodt PLC to $38.00 and set an “outperform” rating on the stock in a report on Wednesday, November 8th. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have issued a buy rating to the company. Mallinckrodt PLC currently has a consensus rating of “Hold” and a consensus price target of $48.14.
In related news, Director David R. Carlucci purchased 10,000 shares of the business’s stock in a transaction dated Thursday, November 9th. The stock was acquired at an average price of $21.83 per share, for a total transaction of $218,300.00. Following the completion of the purchase, the director now directly owns 26,020 shares of the company’s stock, valued at $568,016.60. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Meredith B. Fischer purchased 1,280 shares of the business’s stock in a transaction dated Wednesday, August 30th. The shares were bought at an average price of $39.63 per share, with a total value of $50,726.40. The disclosure for this purchase can be found here. Insiders bought 27,180 shares of company stock valued at $610,166 over the last three months. Corporate insiders own 0.53% of the company’s stock.
Shares of Mallinckrodt PLC (NYSE:MNK) opened at $21.90 on Tuesday. The firm has a market capitalization of $2,067.31, a P/E ratio of 2.94, a PEG ratio of 0.33 and a beta of 1.46. Mallinckrodt PLC has a fifty-two week low of $19.00 and a fifty-two week high of $68.12. The company has a quick ratio of 1.05, a current ratio of 1.38 and a debt-to-equity ratio of 1.08.
Mallinckrodt PLC (NYSE:MNK) last posted its quarterly earnings data on Tuesday, November 7th. The company reported $1.97 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.80 by $0.17. The business had revenue of $793.90 million during the quarter, compared to the consensus estimate of $808.93 million. Mallinckrodt PLC had a return on equity of 14.79% and a net margin of 11.43%. The company’s revenue was down 10.5% compared to the same quarter last year. During the same period in the prior year, the company earned $2.04 earnings per share. sell-side analysts predict that Mallinckrodt PLC will post 7.23 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This article was originally published by Markets Daily and is owned by of Markets Daily. If you are viewing this article on another domain, it was copied illegally and republished in violation of international trademark & copyright legislation. The original version of this article can be accessed at https://www.themarketsdaily.com/2017/11/14/mallinckrodt-plc-mnk-shares-bought-by-aperio-group-llc.html.
Mallinckrodt PLC Company Profile
Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs.
Want to see what other hedge funds are holding MNK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mallinckrodt PLC (NYSE:MNK).
Receive News & Ratings for Mallinckrodt PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt PLC and related companies with MarketBeat.com's FREE daily email newsletter.